Allergens in the Pathogenesis of Asthma
- 1 October 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in American Journal of Respiratory Medicine
- Vol. 1 (5), 361-368
- https://doi.org/10.1007/bf03256629
Abstract
Evidence suggests that allergy is a significant triggering factor in asthma in children and adults alike. In immunoglobulin (Ig) E-mediated allergic reactions, sensitization occurs when allergen-specific B cells are stimulated and switched to IgE antibody production by interleukin (IL)-4 and IL-13 provided by helper T cells type 2 (Th2). The IgE antibodies act by arming cells bearing either the high-affinity (FcεRI) or low-affinity (FcεRII or CD23) receptor. The subsequent interaction of allergen with IgE-FcεRI complexes on mast cells and basophils causes cross-linking of receptors that triggers the release of a variety of inflammatory mediators, cytokines and chemokines. Therefore, the ability to lower circulating free IgE levels is desirable because most individuals are exposed to multiple allergens to which they are sensitive at any given time. Omalizumab (formerly known as rhuMAb-E25) is a recently developed humanized monoclonal anti-IgE antibody directed at the FcεRI binding domain of human IgE. It inhibits binding of IgE to mast cells without provoking mast cell activation. Preliminary clinical data from randomized controlled trials have shown that the addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use. The compound is also well tolerated. Omalizumab represents a novel therapeutic approach in the management of asthma.Keywords
This publication has 51 references indexed in Scilit:
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Drug Treatment of Asthma in the 1990sDrugs, 1999
- Airways Remodelling in Asthma: No Doubt, No More?International Archives of Allergy and Immunology, 1995
- Inhibition of Allergic Reactions with Antibodies to IgEInternational Archives of Allergy and Immunology, 1995
- Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cellsImmunology Today, 1994
- Molecular and biological characterization of a murine ligand for CD40Nature, 1992
- Medication requirements and house dust mite exposure in mite‐sensitive asthmaticsAllergy, 1991
- Human TH1 and TH2 subsets: doubt no moreImmunology Today, 1991
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensThe New England Journal of Medicine, 1989
- Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.The Journal of Experimental Medicine, 1987